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There is growing evidence that people with severe chronic inflammatory diseases may be at higher 
risk of cardiovascular (CV) disease, independent of more traditional CV risk factors. Population based 
studies using primary care databases have demonstrated higher CV risk associated with rheumatoid 
arthritis,1 2 psoriatic arthritis not prescribed a disease-modifying anti-rheumatic drug,2 and severe 
psoriasis.2 However, the subject remains controversial with conflicting evidence.3 Some of the 
ongoing uncertainty may be due to a dose-response effect—increased CV risk is confined to those 
with severe inflammation. 
Previous evidence regarding the risk of CV disease in patients with atopic eczema has been 
inconsistent.4 5 In a linked article, Silverwood and colleagues (doi:10.1136/bmj.k1786) report a study 
using the UK Clinical Practice Research Datalink (CPRD) to iŶǀestigate CV risk iŶ ϯϴϳ ϰϯϵ UK adults 
ǁith atopiĐ eĐzeŵa, ŵatĐhed ďǇ age, seǆ, aŶd loĐatioŶ to ϭ ϱϮϴ ϰϳϳ ĐoŶtrols.6 Moderate disease 
severity was defined by receipt of at least two potent topical corticosteroid prescriptions in one year 
or treatment with a topical calcineurin inhibitor. Severe disease was indicated by phototherapy or 
systemic immunomodulator therapies. 
Data on all standard CV risk factors, such as smoking, hyperlipidaemia, diabetes, and hypertension 
ǁere aǀailaďle iŶ patieŶts’ CPRD records and multivariable analyses controlled for these 
confounders. During an average of five years of follow-up after initial diagnosis, the risk of CV death 
was 30% higher in patients with severe eczema, heart failure risk was 70% higher and risks of 
myocardial infarction, unstable angina, and atrial fibrillation were about 40% higher than in controls. 
Severe eczema was associated with a 20% increased risk of stroke, with a 99% confidence interval 
for the adjusted hazard ratio of 1.01 to 1.48, i.e. just reaching significance. A dose-response effect 
was observed, with CV  risks increasing from mild to moderate to severe eczema. Adjusted risks 
were attenuated when all atopic eczema was grouped together but remained significant for most CV 
outcomes.  
Silverwood and colleagues also considered the effect of disease activity, identifying patients who 
had at least two eczema entries a year in their records for more than half of their follow-up period. A 
similar dose-response effect was observed, albeit with smaller magnitude of effects. Strengths of the 
study include its large sample size and data acquisition from primary care, allowing a full spectrum of 
disease severity to be included. Availability of relatively comprehensive records of standard CV risk 
factors in CPRD allowed most potential confounders to be accounted for in the multivariable 
analysis. The dose-response effect observed with both eczema severity and eczema activity supports 
the observed association. 
The authors used a validated algorithm to identify patients with atopic eczema, consisting of entry of 
an atopic eczema diagnostic Read code in CPRD combined with two separate atopic eczema 
treatment codes. The algorithm has a positive predictive value of 82% (95% confidence interval 73% 
to 89%) in identifying patients with atopic eczema. Turning this figure on its head means that one 
fifth of the patients in the exposed cohort did not have atopic eczema, however this would tend to 
attenuate the magnitude of the hazard ratios observed. One additional point is that, while the 
authors adjusted for acquired CV risk factors, it is possible that shared genetics between atopic 
eczema and CV disease represents an unadjusted confounder, because a family history of CV disease 
was not included in the multivariable analysis. 
A sensitivity analysis investigating the use of high dose oral corticosteroids was consistent with the 
main analysis. However, the authors make the point that their results cannot differentiate the 
disease from treatment. For example, there may be a systemic effect of prolonged topical 
corticosteroid application on the CV system. 
What are the implications for patients and doctors? For patients with severe or more active eczema, 
the evidence from the Silverwood and colleagues study makes the case for targeted screening of 
standard CV disease risk factors. We may need to rethink thresholds for primary prevention 
interventions in this patient group, by factoring in severe eczema as an independent CV disease risk 
factor. 
The results may also have ramifications for allocation of healthcare resources in eczema. Prevention 
of CV disease by better control of severe eczema will contribute to the justification for expensive 
next generation biologic drugs that are becoming available for atopic eczema. Exploring whether 
these eczema drugs reduce CV events in patients with severe eczema is the next important step. 
One further extrapolation is to consider CV disease prevention as a potential outcome in long term 
eczema trials. 
The results from Silverwood and colleagues have helped to clarify the conflicting evidence regarding 
atopic eczema and CV risk. Severe eczema has joined a growing list of chronic inflammatory 
conditions that may, in those with severe disease activity, contribute an independent increase in CV 
disease risk. 
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